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1. Introduction 
The placenta, essential for normal fetal development by providing adequate nutrients to 
allow appropriate growth and maturation of the fetus in preparation for birth, is also a 
‘protective’ barrier in the sense that it prevents entry into the fetal circulation of substances 
that are either toxic, or that drive fetal growth at inappropriate rates. An important aspect of 
this ‘filtering’ function of the placenta is limiting the entry of glucocorticoids of maternal 
origin into the fetal compartment. This is achieved by the presence of enzymes, transporters 
and receptors collectively termed the ‘placental glucocorticoid barrier’ [1-4]. 
Antenatal glucocorticoids are routinely administered to the mother for the treatment of a 
variety of pregnancy and fetal complications. Asthmatic women often experience an 
increase in severity of their symptoms during pregnancy leading to increased use of 
glucocorticoids. The threat of preterm birth results in administration of the synthetic 
glucocorticoid, betamethasone, to rapidly mature fetal organs (especially, the lungs) to 
promote survival. Further, stressful events during pregnancy such as natural disasters and 
famines for example, expose fetuses to higher than normal levels of maternally secreted 
glucocorticoids.  
The effects of exposure to high levels of glucocorticoids during fetal development have now 
been well described [1, 5-9], and the advantages (e.g., maturation of lung surfactant 
production and increased hepatic glycogen deposition) are offset by effects that limit fetal 
growth and induce perturbations of brain growth and perfusion [1, 10-11]. However, while 
fetal/neonatal effects have been intensively investigated, the consequences of glucocorticoid 
excess on placental structure and function has received little attention to date. The 
knowledge that male fetuses are more likely to be affected negatively following events that 
usually increase fetal glucocorticoid exposure, has alerted researchers to the possibility that 
such sex-related effects could arise in the placenta. This chapter will describe the differences 
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that exist between a male and female placenta with respect to the glucocorticoid barrier, and 
summarise current human clinical and experimental animal work that has explored the 
differential response of the placenta of a male and female fetus to glucocorticoid exposure.  
2. The placental glucocorticoid barrier 
While glucocorticoids are essential for the development of many organs, during 
pregnancy, the placenta acts as a barrier to prevent excess entry of maternal glucocorticoids 
into the fetal compartment [12-14]. This placental barrier to glucocorticoids is achieved 
predominantly by the presence of 11β-hydroxysteriod dehydrogenase type 2 (11βHSD2), 
which converts the biologically active glucocorticoid (cortisol in humans, corticosterone in 
mice and rats) to its physiologically inert form [2]. The placental ‘barrier’ is not complete, 
and under normal conditions a proportion (~10-15%) of maternal glucocorticoids reaches 
the fetal circulation [2]. While 11βHSD2 is the major component of the placental 
glucocorticoid barrier, other proteins contained within the placenta may also help to limit 
the transfer of maternal glucocorticoid to the fetus. The multi-drug resistance P-
glycoprotein (ABCB1) is a membrane-bound protein, which mediates the efflux of 
glucocorticoids out of the placenta back into the maternal circulation, thus reducing the 
amount of glucocorticoids able to diffuse down the concentration gradient into the fetal 
circulation [15-17].  
The response of the placenta itself to glucocorticoids is mediated by the glucocorticoid (GR) 
and mineralocorticoid receptor [18]. The most prominent isoform of the GR, both in the 
placenta and throughout the whole body, is GRα. This isoform mediates the biological 
effects of glucocorticoids, which include cell growth, proliferation and differentiation [19]. 
The placenta has not generally been considered a mineralocorticoid target tissue, however 
work by Driver et al [20] has suggested that placental trophoblast cells express a functional 
mineralocorticoid receptor, which is in part responsible for the transport of sodium across 
the placenta [20]. Because of the limited data on the role of the mineralocorticoid receptor in 
the placenta, our discussion will focus primarily on GR mediated effects. 
3. Causes of elevated glucocorticoids during pregnancy 
There are many circumstances during pregnancy in which the circulating levels of maternal 
glucocorticoids are elevated, resulting in placental and fetal exposure to excess 
glucocorticoids. The glucocorticoids within the maternal system can either be endogenous, 
originating from within the mother; or exogenous, where the glucocorticoid has been 
administered to the mother as a drug or treatment. Exogenous glucocorticoids are generally 
synthetic, such as betamethasone, dexamethasone or prednisone. The period of time when 
maternal, and therefore fetal and placental glucocorticoid levels, are elevated will vary 
considerably depending on the clinical circumstance, and effects arising from either acute or 
chronic exposures have been identified. Thus, the type of glucocorticoid, duration of 
exposure, and time in gestation need to be taken into account when determining the 
consequences for the fetus and placenta. 
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3.1. Exposure to natural glucocorticoids 
Periods of stress, both physical (illness, excess exercise, famine/under nutrition) or 
psychological (anxiety) in origin, result in the elevation of endogenous glucocorticoids [21]. 
While cortisol can cross the placenta, it is a good substrate for 11βHSD2, and is readily 
catalysed by this enzyme under normal levels. However, when levels of cortisol are 
elevated, the barrier is overwhelmed and more cortisol is able to cross the placenta into the 
fetal circulation [4]. Deleterious effects of excess endogenous glucocorticoids on the fetus 
and newborn have been well documented [3, 6, 22-25]. These effects are greater for male 
fetuses. For example, males have been shown to have greater instances of in utero mortality 
and also increased likelihood of childhood and adult morbidity and mortality [21, 26]. An 
epidemiology study that examined women who were pregnant at the time of the 2001 
terrorist attacks on the World Trade Centre found that there was a higher incidence of low 
birth weight babies for women who were residing in New York at the time. The greatest 
proportion of these low birth weight babies came from women who were in their first or 
second trimester at the time of the attacks [27]. These studies also revealed an increased 
incidence of male fetal death in New York after September 2001 [28-29]. High maternal 
stress and thus fetal exposure of cortisol are thought to be the cause of these poor fetal 
outcomes.  
3.2. Exposure to synthetic glucocorticoids 
Antenatal glucocorticoids are routinely administered to the mother for the treatment of a 
variety of pregnancy and fetal complications. Women who suffer from asthma are required 
to continue their glucocorticoid medication for the ongoing treatment/prevention of their 
symptoms, which in 33% of cases worsen during pregnancy [30-31]. Women whose babies 
are at risk of congenital adrenal hyperplasia are administered antenatal glucocorticoid 
treatment to return fetal adrenal hormone levels to normal and thus virilisation (the 
abnormal development of male sexual characteristics in a female) and fertility problems are 
prevented [32]. Further, pregnant mothers threatening preterm birth (~7-10% of all 
pregnancies), receive antenatal glucocorticoids, to mature the lungs of the fetus prior to 
birth to reduce neonatal morbidity and mortality [25]. As for cortisol, synthetic 
glucocorticoids can be catalysed by 11βHSD2, however they are a poor substrate for the 
enzyme, and more freely cross the placenta than cortisol [33]. The presence of excess 
maternal glucocorticoids can have positive effects on fetal development and maternal health 
and in many situations cannot be avoided. The National Institute of Health recommend 
treatment of all women at risk of preterm delivery, between 24 and 34 weeks of gestation, 
with synthetic glucocorticoids to prematurely mature fetal organs, primarily the lung, to 
improve neonatal survival [8]. Therefore a large proportion of this population of babies, are 
exposed to single, and sometimes multiple courses of synthetic glucocorticoids in the period 
leading up to birth [25]. While antenatal glucocorticoids are the most effective treatment for 
improving preterm birth survival rates, the scientific community continues to question 
whether the use of glucocorticoids to reduce the morbidity and mortality associated with 
preterm birth, is worth the risk of the potential negative outcomes on metabolism and 
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neurodevelopment seen within these babies during childhood and into adulthood [9]. While 
the consensus is currently ‘yes’, the guidelines for women threatening preterm birth state 
that only a single, and not multiple doses of glucocorticoids, should be given until more 
convincing data of the benefits of multiple doses are obtained [34]. Much work is examining 
the outcomes of antenatal glucocorticoids for the fetus, however the effect of glucocorticoids 
on the placenta, including the potential sex-specific effects, need to be considered as these 
may contribute to, or compound, the fetal outcomes. 
4. Excess glucocorticoids and the programming of disease  
The Barker Hypothesis of Developmental Origins of Health and Disease (DoHaD) states that 
diseases, such as coronary heart disease, hypertension and diabetes, may be consequences of 
in utero 'programming', whereby a stimulus or insult at a critical, sensitive ‘window’ of fetal 
life results in long-term changes in structure, physiology or metabolism, leading to diseases 
later in life [35]. These stimuli are likely to be mediated via a number of different hormones 
and immune factors, but glucocorticoids have been singled out as one of the most prevalent 
factors. Epidemiological and experimental animal studies have revealed that excess 
glucocorticoids in utero can be linked to the development of diseases such as hypertension 
[36-42], depression [43], cardiovascular disease [44], diabetes [45-46] and attention deficit 
disorders [23, 47]. Further, the outcomes or the severity of these diseases are worse if the 
offspring affected are male [37-39, 48-51].  
Recently, a role for the placenta in mediating developmental programming of excess 
glucocorticoids and other in utero events has been suggested [44, 47, 52-55]. The size (both 
absolute and relative to fetal size), shape, and vascular development of the placenta have all 
been identified as potential predictors of adult onset diseases. For instance, a small baby with 
a large placenta has a relative risk of adult hypertension 3 times that of a large baby with a 
normal placental size [44]. Further, the abolition of a gene vital for placental, but not cardiac 
vascular development (HOXA13) has been shown to be embryonic lethal in mice, indicating 
that placental hemodynamics play an important role in the development of the heart, and 
alterations may lead to the development of cardiovascular problems later in life [56]. 
5. Susceptibility of the placenta to negative outcomes from glucocorticoid 
exposure 
There are several reasons for the susceptible of the placenta to adverse outcomes caused by 
excess glucocorticoid exposure. I.) The placenta is in direct contact with the maternal 
circulation and thus is directly bathed in circulating maternal glucocorticoids. II.) One of the 
main roles of the placenta, as described above, is as a barrier to prevent fetal exposure to excess 
glucocorticoids; therefore the placenta may be directly altered by the glucocorticoid exposure 
before 11βHSD2 is able to convert these to their inactive metabolites [57]. III.) The structural 
development of the placenta occurs through a series of branching events, particularly the 
placental vasculature. This branching occurs similarly in other organs, such as the lung and 
kidney, which are particularly vulnerable to excess glucocorticoid exposure during periods of 
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extensive branching [58-60]. Indeed in the evolution of the placenta, the genetic pathways that 
regulate branching morphogenesis in these other organs has been utilised by the placenta [61-
65]. Hence a similar susceptibility could be expected for the placenta.  
6. Sex-specific placental regulation of glucocorticoids 
The placental is primarily derived from embryonic tissue and therefore has the same genetic 
content as the fetus. In recent studies examining both human and animal models, a number of 
fundamental differences between the placenta of a male and female fetus have been 
uncovered. Differences in placental proportions [66] and surface area [67] have been noted in 
placentas of males and females. Specifically, females have been shown to have a greater 
exchange region of the placenta compared to males [66], and within this exchange region, 
females have been reported to have a larger surface area [67]. Expression of genes and proteins 
known to have fundamental roles in controlling placental development [66], nutrient transfer, 
and other placental functions [68-71] differ between a male and female placenta. Specifically, 
placentas of male fetuses have been reported to have higher levels of the glucose transporter 
[66], higher levels of epidermal growth factor binding protein at term [68], but lower levels of 
activity of the sodium-hydrogen exchanger [70]. Levels of pregnancy hormones, produced by 
the placenta, differ for a male and female. For example, maternal serum human chorionic 
gonadotrophin levels are significantly higher in pregnancies carrying a female fetus from as 
early as 3 weeks of pregnancy [72]. Placental levels of progesterone also differ for a male and 
female fetus in many species, with a study in the gray seal, for example, showing higher levels 
in females than males [73]. Because progesterone is primarily of placental origin, these 
differences provide further evidence of the fundamental differences that exist in the placenta 
of a male and female fetus. Further, the placenta of a male and female fetus have also been 
shown to respond differently to adverse in utero environments including maternal under-
nutrition/famine [74] and in utero infection [75]. For example, female placentas demonstrated 
more striking alterations in gene expression in response to restrictions in maternal diet than 
male placentas when examined by microarray analysis. Further, placentas of male fetuses 
exhibited a greater immunologicial reaction (greater expression of TNFa, IL-10, and PTGS2) to 
simulated in utero infection. Whether these responses differ because of the fundamental 
differences that exist between the sexes remains unknown. 
Normal physiological glucocorticoid levels: During pregnancy, the term female placenta 
has significantly higher expression of the GR [31] and 11βHSD2 activity [76] than placentas 
of male fetuses. Glucocorticoids are known to negatively regulate GR expression [66, 77], 
therefore the higher GR expression within placentas of female fetuses may be physiological 
evidence that the female fetal–placental unit is exposed to less bioactive cortisol at term than 
the male. A downstream consequence of lower glucocorticoid levels may be an enhanced 
immune response. The activation of the fetal immune system is associated with the 
activation of the fetal hypothalamic pituitary adrenal axis, which results in the production of 
glucocorticoids, which in turn modulate the inflammatory response. Glucocorticoids 
function in a negative feedback loop with the hypothalamic pituitary adrenal axis, such that 
high glucocorticoid levels suppressing immune function [78]. It has been suggested that this 
 
Glucocorticoids – New Recognition of Our Familiar Friend 396 
may contribute to the increased viability of female fetuses exposed to a sub-optimal in utero 
environment, compared to males, who are particularly vulnerable to changes in the 
maternal environment in which increased levels of glucocorticoids are often seen [79] (see 
above).  
Response to excess glucocorticoids: The adverse effects of glucocorticoids during 
pregnancy on placental weight in the human have been reported as early as 1977 by Koppe 
and others [80]. Since then, a number of studies, in both humans and animal models, have 
demonstrated that excess glucocorticoids during gestation have a wide range of 
consequences for the placenta, which impact its structure and function, ultimately impacting 
the fetus [22, 81-91]. Recently, these consequences have been shown to occur in a sex-specific 
manner. 
Human evidence 
Evidence is beginning to emerge from studies in the clinical setting demonstrating that 
human placentas are sexually dimorphic in their regulation of normal glucocorticoid levels 
and these differences are exacerbated in response to excess maternal glucocorticoids. Much 
of this clinical evidence is arising from the work of Clifton and colleagues, who focus on 
identifying the effect of glucocorticoids on fetal and placental development, by studying 
mothers who suffer from asthma and thus use inhaled glucocorticoid treatments throughout 
their pregnancy. Asthma affects between 3% and 12% of pregnant women worldwide and 
the prevalence among pregnant women is rising [92]. It is well recognised that women (and 
their babies) with asthma are at increased risk of poor pregnancy outcomes [93]. Clifton and 
colleagues have also examined preterm babies and the consequences of excess 
glucocorticoid exposure on their placentas.  
6.1. Effect of glucocorticoids on placental development and other pathways 
Female babies born to asthmatic mothers, who utilised inhaled glucocorticoid treatments to 
manage their symptoms, were found to be growth-reduced unlike male babies born to 
asthmatic mothers, who were normally grown, despite similar cord blood cortisol levels 
[76]. Placentas of male and female babies born to these mothers, had reduced vascularisation 
within the placental villi, resulting in reduced absolute fetal capillary volume [94], although 
this was most striking in placentas of male fetuses. Further, placentas of glucocorticoid-
exposed males also had a reduced fetal capillary length [94], which was not observed in 
placentas of female fetuses. The authors speculate that glucocorticoid treatment may 
adversely affect placental vasculogenesis and/or angiogenesis by causing endothelial cell 
rounding and capillary regression, an observation made in other tissues after glucocorticoid 
exposure [95-97]. These effects may be mediated by members of the vascular endothelial 
growth factor family or inflammatory cytokines, both of which play a key role in placental 
vasculogenesis and angiogenesis [98]. The observed changes in placental morphometry in 
male placentas would be expected to affect placental heamodynamics, however the absence 
of these changes in the female placenta do not adequately explain the reduced fetal growth 
of the female fetus in this high glucocorticoid environment. 
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A study by Stark et al [99], examined the placental pro-: anti-oxidant balance in response to 
antenatal betamethasone in placentas of preterm babies. Glucocorticoids have previously 
been shown to influence fetal reactive oxygen species production and antioxidant defences 
[100-101]. These pathways are involved in preparing the fetus for the increase in free oxygen 
radical generation which is experienced during the fetal to neonatal transition [102]. Stark 
and colleagues observed that a pro-oxidant state was present in placentas of male fetuses, 
but not females following glucocorticoid exposure. Specifically, they reported that males 
had higher levels of the oxidative stress marker, protein carbonyl and a decreased level of 
the anti-oxidant enzyme, glutathione peroxidase. The authors suggested that these findings 
could contribute to the patho-physiologic processes underlying oxygen radical diseases of 
the newborn [99]; conditions known to exhibit a male excess [103]. 
6.2. Sex-specific effects of excess glucocorticoids on the placental glucocorticoid 
barrier 
As the placental glucocorticoid barrier demonstrates sexually dimorphic regulation under 
normal conditions, and the placental response to glucocorticoids is crucial in determining 
fetal growth outcomes, the effect of excess maternal glucocorticoids on this barrier have 
been investigated. The expression of the GR within the placenta of male and female fetuses 
is reported to be sexually dimorphic under normal conditions (females having higher 
expression levels), whereas the response of GR to excess glucocorticoids is similar between 
the sexes [77].  
In preterm babies, whose mothers received antenatal betamethasone, the activity of 
placental 11βHSD2 (predominant component of the glucocorticoid barrier) was reduced in 
placentas of male fetuses only [104]. This reduction in 11βHSD2 activity would be expected 
to compound the already increased exposure of the male fetus to cortisol brought about by 
the decreased term 11βHSD2 activity within male placentas during a normal pregnancy 
[76]. This may further compound the reduced immune function in male fetuses, thus 
increasing their susceptibility to disease. Further, glucocorticoids are important for fetal 
adrenal development [104]. Male preterm babies exposed to excess glucocorticoids in utero, 
have less adrenal activity than female preterm babies exposed to similar levels of 
glucocorticoids [104], which may explain the increased risk of morbidity and mortality of 
preterm male babies. We are unaware of any studies that have investigated the other 
members of the placental glucocorticoid barrier (MR and ABCB1) and their sexually 
dimorphic response to excess glucocorticoid exposure. 
Animal models of glucocorticoid exposure 
The effects of excess maternal glucocorticoid exposure, on placental growth and 
development, has been investigated using a range of animal models including the sheep 
[105-106], rat [85], mouse [107] and spiny mouse [66]. Most of these studies have utilised 
synthetic glucocorticoids (namely dexamethasone or betamethasone) and been designed to 
mimic the level of exposure experienced by the preterm infant. However, there are also a 
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large number of studies using glucocorticoids at other developmental time points including 
very early in gestation. When considering the data generated from animal models, it is 
important to take into consideration not only the timing of glucocorticoid exposure but also 
the timing of placental and fetal development in the species being used, as there is 
considerable variation in placental development and overall structure between species. 
Many of these studies, particularly those in the sheep and rat, have not analysed data 
according to fetal sex. However a couple of recent studies in the mouse and spiny mouse 
have demonstrated markedly different outcomes in placental development and gene 
expression in placentas of males and females suggesting that alterations occurring within 
the placenta, following glucocorticoid exposure, are dependent upon fetal sex.  
Sheep 
The sheep placenta is made up of 60-70 individual placentomes called cotyledons, which are 
cup shaped structures with fetal tissue surrounded by maternal tissue. Administration of 
dexamethasone for 48 hours between 64-66 days of gestation (term=145-150 days) resulted in 
generally larger cotyledons with overgrowth of the fetal tissue when the placenta was 
examined at completion of the infusion [105]. However, this was not observed in other 
studies using betamethasone later in gestation (around 100 days of gestation) [108]. 
Unfortunately, neither of these studies separated data according to fetal sex. In another 
study, pregnant ewes received intramuscular injections of dexamethasone on day 40 and 41 
of gestation and the placentas were examined at day 50, 100 or 140 days of gestation. In this 
case, data was analysed separately for males and females and whilst dexamethasone 
exposure significantly increased placental 11βHSD2 mRNA levels in males compared with 
controls at 50 and 140 days, in female placentas, levels were not altered by the 
dexamethasone exposure [106].  
Rat 
Dexamethasone exposure during late pregnancy has been shown to significantly reduce 
placental weight in the rat [91, 109]. This was associated with reduced expression of vascular 
endothelial growth factors (VEGF) and placental vascularisation [91] along with altered 
insulin like growth factor II expression. Neither of these studies looked at sex-specific 
effects. 
Mouse  
Given the extensive use of the mouse for development studies, it is somewhat surprising that 
there has been little research of the effects of glucocorticoids on the mouse placenta. We have 
recently shown that dexamethasone exposure for 2 days around mid-gestation (day 12.5-14.5 
of gestation, term=20 days) caused decreases in fetal body weight at day 14.5, but placental 
weight was only reduced in placentas from female fetuses [107]. These changes in placental 
growth were associated with sex-specific changes in placental gene and protein expression: at 
day 14.5, the placentas from female fetuses had higher mRNA levels of expression of 
11βHSD2 and VEGF, whilst protein levels of Mitogen-activated protein kinase were 
significantly reduced. By day 17.5, some 3, days after cessation of the dexamethasone, fetal 
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and placental weights are restored but levels of 11βHSD2 protein are elevated in the 
placentas of female fetuses. These sex-specific changes in gene and protein levels were not 
present for nutrient transporters such as glucose transporter 1 and 3 or the major amino acid 
transports [107]. 
Spiny mouse 
We have also utilised a precocial rodent, the spiny mouse (Acomys cahirinus), in which the 
natural circulating glucocorticoid is cortisol, not corticosterone like other rodents [110], to 
explore sex-specific effects of glucocorticoids on the placenta. O’Connell et al [66] examined 
the immediate and long-term consequences of excess maternal glucocorticoids 
(dexamethasone) administered for a short time (60h) at mid-gestation (day 20, term is 39 
days) on placental structure and gene expression. The immediate consequences of 
glucocorticoid administration were similar between male and female placentas. However, 
two-weeks post-treatment (day 37), the transcriptional and structural response of the 
placenta was dependent on the sex of the fetus. Placentas of male fetuses were found to 
have an increase in the expression of a gene involved in placental patterning, glial cell 
missing 1 gene; GCM1, but also decreases in the expression of the primary placental glucose 
transporter (solute carrier family 2 (facilitated glucose transporter), member 1; SLC2A1). 
Placentas of male fetuses also had decreased amounts of maternal blood sinusoids, which 
are involved in the drawing of nutrient poor blood away from the placenta and back into 
the maternal circulation. Placentas of female fetuses were observed to have increased 
glucose transporter expression, and an increased amount of maternal blood sinusoids, in 
other words, the response of a female placenta to excess glucocorticoids was opposite to that 
of a male. This study highlights that while the immediate response to excess glucocorticoids 
may be the same for both sexes in this species, these may persist or evolve within the 
placenta differently, depending on the sex of the fetus [66]. 
7. Significance 
There is now a growing body of evidence to suggest that the placenta of a male and female 
differs and that this may underlie the greater vulnerability of males to stressors that occur 
during pregnancy. Here we provided evidence that the placental response to changes in 
maternal glucocorticoid status differs depending on the sex of the fetus and raises the 
important question: are differences in fetal outcomes driven by the fetus itself or the 
placenta. We suggest that the placenta should become an organ of greater interest to 
clinical obstetrics and perinatology, particularly with respect to how the placenta may 
function differently for a male and female fetus during periods of high glucocorticoid 
exposure.  
With respect to the clinical use of glucocorticoids, the different response of a male and 
female to even a small dose of synthetic glucocorticoids must be followed up in a large 
clinical based study. At least from experimental data, the question has been raised, “Should 
the sex of the fetus be taken into consideration when synthetic glucocorticoids are 
administered during pregnancy”? 
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